Abstract
Objective. The objective of this analysis was to compare clinical and cost outcomes associated with patients who had suspected or documented methicillin-resistant Staphylococcus aureus (MRSA) infections treated with daptomycin, vancomycin, or linezolid in complicated skin and skin structure infections (cSSSIs). Design. This was a retrospective analysis conducted from February to June of 2007. Appropriate data was collected, collated, and subsequently evaluated with the purpose of quantifying length of stay, antibiotic therapy duration, clinical cure rates, adverse drug events, and cost of hospitalization. Results. All 82 patients included in the analysis experienced clinical cure. The duration of antibiotic therapy was similar among the three groups yet the length of hospitalization was slightly shorter in the daptomycin group. Conclusions. The incidence of resistant staphylococcal infections is increasing; therefore, judicious use of MRSA active agents is paramount. Future studies are necessary to determine if MRSA treatment options can be stratified based on the severity of the infectious process.
References
Nov 1, 1987·Reviews of Infectious Diseases·S D HolmbergP A Blake
Mar 1, 1981·Infection Control : IC·J M BoyceH L DuPont
Aug 1, 1981·Clinical Pharmacology and Therapeutics·C A NaranjoD J Greenblatt
May 17, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Dennis L StevensBarry Hafkin
Feb 21, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John J EngemannKeith S Kaye
May 6, 2003·Diagnostic Microbiology and Infectious Disease·Robert P RennieUNKNOWN SENTRY Program Study Group (North America)
Jul 1, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Robert D ArbeitUNKNOWN Daptomycin 98-01 and 99-01 Investigators
May 27, 2005·Antimicrobial Agents and Chemotherapy·John WeigeltUNKNOWN Linezolid CSSTI Study Group
Nov 18, 2005·International Journal of Antimicrobial Agents·Kamal M F ItaniSandeep Duttagupta
Jan 5, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R Monina KlevensUNKNOWN National Nosocomial Infections Surveillance System
May 25, 2006·The Annals of Pharmacotherapy·Peggy S McKinnonKamal Mf Itani
Sep 8, 2006·Journal of Clinical Microbiology·Guiqing WangDavid A Bruckner
Oct 25, 2006·Diagnostic Microbiology and Infectious Disease·Gary J MoetThomas R Fritsche
Feb 14, 2007·The American Journal of Geriatric Pharmacotherapy·Robert L Page, J Mark Ruscin
Jul 12, 2007·The Journal of Antimicrobial Chemotherapy·Gregory SteinkrausLawrence Friedrich
Sep 19, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Scott T Micek
Oct 13, 2007·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Deverick J AndersonKeith S Kaye
Oct 16, 2007·American Journal of Surgery·Samir S AwadDavid H Berger
Nov 29, 2007·Pharmacotherapy·Susan L DavisMichael J Rybak
Citations
Dec 29, 2012·Core Evidence·Richard R WatkinsThomas M File
Dec 19, 2014·Chemical Biology & Drug Design·Talitha I Verhoef, Stephen Morris
Jun 30, 2014·Mayo Clinic Proceedings·Alpesh N AminBradley M Sherman
Oct 1, 2013·Journal of Pharmacy Practice·Cyrus Yazdani, Nancy Hanna
May 31, 2013·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Xingyue HuangH David Friedland
Dec 3, 2014·PharmacoEconomics·Fernando AntonanzasCarmen Torres